HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): William R. Wagner Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Snyder, T. A. Articles by Wagner, W. R. Search for Related Content PubMed PubMed Citation Articles by Snyder, T. A. Articles by Wagner, W. R.

Ann Thorac Surg 2002;73:1933-1938
© 2002 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Platelet activation, aggregation, and life span in calves implanted with axial flow ventricular assist devices

^a Department of Bioengineering, Pittsburgh, Pennsylvania, USA
^b Department of Surgery, Pittsburgh, Pennsylvania, USA
^c McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Accepted for publication February 7, 2002.

* Address reprint requests to Dr Wagner, 328 Scaife Hall, University of Pittsburgh, 3550 Terrace St, Pittsburgh, PA 15213 USA
e-mail: wagnerwr{at}msx.upmc.edu

Background. A variety of rotary blood pumps are under development worldwide to serve as chronic ventricular assist devices (VADs). Historically VADs have been associated with thrombotic and thromboembolic complications, yet the ability to evaluate the thrombotic process in preclinical device testing has been limited.

Methods. We have developed and applied flow cytometric assays for activated platelets, platelet microaggregates, and platelet life span and consumption to calves implanted with an axial flow VAD and calves undergoing a sham surgical procedure.

Results. Surgical sham calves had significant increases in circulating activated platelets (p < 0.05) that resolved within 17 days, and no increases in circulating platelet microaggregates. Calves with uneventful VAD implant periods had early transient elevations in platelet microaggregates and prolonged elevations in activated platelets that did not recover to preoperative values during the study. Daily platelet consumption in VAD implanted calves was increased by 20% ± 3%. Calves with thrombotic deposition within the VAD and elevated thromboembolism observed at autopsy experienced increases in circulating activated platelets and microaggregates at the end of the implant period when VAD flow decreased.

Conclusions. This study demonstrates the ability of flow cytometry-based platelet assays to differentiate VAD implant operations from VAD support, and suggests differences that exist between uneventful VAD support and support with complications. These techniques should have value in evaluating other cardiovascular devices undergoing preclinical testing and provide insight into the temporal impact of these devices on the hemostatic system.

This article has been cited by other articles:

				K. Doi, L. A. R. Golding, A. L. Massiello, M. W. Kopcak Jr, R. L. Gerhart, S. Schenk, M. Inoue, Y. Ootaki, and K. Fukamachi Preclinical readiness testing of the arrow international CorAide left ventricular assist system Ann. Thorac. Surg., June 1, 2004; 77(6): 2103 - 2110. [Abstract] [Full Text] [PDF]